Moderna : Guidance 21 ajustée à la hausse relevée – Des perspectives de croissance réitérées
>Premier trimestre bénéficiaire du groupe - Moderna a publié hier ses résultats du T1 2021, historiquement son premier trimestre bénéficiaire. Tandis que la topline ressort légèrement en dessous des attentes à 1.93 Md$ (vs Cs à 2 Md$), la profitabilité est, quant à elle, plus élevée qu’attendu avec un résultat net de 1.2 Md$ (vs 832 M$ attendus). Une surperformance due en partie à des COGS moins élevés qu’anticipé (11% des ventes vs 23% attendu) sous l’effet de la com...Moderna is creating a new generation of medicines based on messenger RNA to improve the lives of patients. The company uses its platform to identify and develop new mRNA medicines. When the company identifies a combination of platform technologies or programs across mRNA technologies, delivery technologies, and manufacturing processes that can enable shared product features across multiple potential mRNA medicines, it groups those programs as a modality. The company has created six modalities including prohylactic vaccines; cancer vaccines; intratumoral immuno-oncology; localized regenerative therapeuctics; systemic secreted therapeutics; and systemic intracellular therapeutics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.